Home / Community / News / News

News

01/28/2016 - 7:35am

The use of anesthesia raises special risks to DM patients, which include heightened sensitivity to sedatives and analgesics. Serious complications are most common in the post-anesthesia period when risk of aspiration and other complications are increased. Click here for a handy, one-page summary of the anesthesia guidelines to share with your clinician and anesthesiologist. The complete "Practical Guidelines for the Anesthetic Management of a Myotonic Dystrophy Patient" will be available in February 2016.

01/14/2016 - 12:32pm

Word came from the FDA on January 14th that it would not approve the new drug application for "Kendrisa,"  Biomarin's antisense-oligo based drug for Duchenne muscular dystrophy.

12/02/2015 - 11:36am

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

11/16/2015 - 2:44pm

The Myotonic Dystrophy Foundation partnered with Silicon Valley Research Group to develop a survey to better understand how people with DM weigh the benefits of new treatments again the risks. 

11/04/2015 - 10:18am

More information and a clarlification on the second-generation ISIS-DMPKRx drug report from the October MDF Dispatch.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.